Arrowstreet Capital
CTSO icon

Arrowstreet Capital’s Cytosorbents Corp CTSO Stock Holding History

Arrowstreet Capital’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-38,139
Closed -$378K – 2360
2020
Q2 		$378K Buy
+38,139
New +$350K ﹤0.01% 2039

Other funds holding CTSO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arrowstreet Capital's CTSO Position: Q3 2020 in Review

Arrowstreet Capital sold out of Cytosorbents Corp (CTSO) in Q3 2020, closing a stake of 38,139 shares — an estimated $378K sold.

Arrowstreet Capital first reported a position in CTSO in Q2 2020 and held it in 1 quarter. The position peaked at $378K in Q2 2020. 96 funds tracked by Wall St. Rank hold CTSO as of Q3 2020.

  • Arrowstreet Capital reported no remaining Cytosorbents Corp position as of Q3 2020 after selling out during the quarter.
  • Arrowstreet Capital sold 38,139 Cytosorbents Corp shares in Q3 2020, an estimated $378K.
  • Arrowstreet Capital first reported a position in Cytosorbents Corp in Q2 2020 and held it in 1 quarter.
  • Arrowstreet Capital's Cytosorbents Corp position peaked at $378K in Q2 2020.
  • 96 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q3 2020.

Based on Arrowstreet Capital's 13F filing for Q3 2020, filed 12 Nov 2020.